- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
tim889 发表于 2022-9-17 09:55
“最新消息是长期使用NA可以沉默cccDNA” 请问文献出处?
http://hbvhbv.info/forum/thread-1761197-1-1.html
http://hbvhbv.info/forum/thread-1761195-1-1.html
"The authors suggested their findings support a role for NA in transcriptional silencing of cccDNA but not a reduction in the number of infected cells. They further suggested that in patients whose HBsAg is mainly derived from iDNA, continuation of NA therapy will not achieve additional reduction in HBsAg levels and different therapies, targeting iDNA-derived HBV S transcripts or cells that produce them, will be needed (15). These findings conflict with other studies that have not reported an effect of NAs on cccDNA transcription or elimination (16). It is possible that a decline in cccDNA transcription after many years of NA therapy may be due to decreased nucleocapsid recycling and intracellular replenishment of cccDNA. Alternatively, not all hepatocytes targeted for microdissection harbored HBV infection, as no marker of infection was used for selecting HBV-infected hepatocytes (15)."
作者建议他们的发现支持 NA 在 cccDNA 转录沉默中的作用,但不支持感染细胞数量的减少。 他们进一步建议,在 HBsAg 主要来自 iDNA 的患者中,继续 NA 治疗不会进一步降低 HBsAg 水平,需要针对 iDNA 衍生的 HBV S 转录物或产生它们的细胞的不同疗法 (15)。 这些发现与其他未报道 NA 对 cccDNA 转录或消除影响的研究相冲突 (16)。 多年 NA 治疗后 cccDNA 转录的下降可能是由于核衣壳循环减少和 cccDNA 的细胞内补充。 或者,并非所有针对显微切割的肝细胞都存在 HBV 感染,因为没有使用感染标记物来选择 HBV 感染的肝细胞 (15)。
"The findings from Grudda et al. (15) and other studies showing that iDNA can be a predominant source of HBsAg in some patients, particularly those who are HBeAg-negative (12), and the low rates of HBsAg loss achieved in ongoing trials of emerging therapies that specifically target HBsAg (17), have raised the question whether HBsAg loss is a valid definition of functional HBV cure and if it is achievable. "
Grudda 等人的研究结果。 (15) 和其他研究表明,iDNA 可能是某些患者 HBsAg 的主要来源,尤其是那些 HBeAg 阴性的患者 (12),并且在针对 HBsAg 的新兴疗法正在进行的试验中实现了低 HBsAg 丢失率。 17),提出了 HBsAg 消失是否是功能性 HBV 治愈的有效定义以及是否可以实现的问题。 |
|